抗PD-1/PD-L1单抗药物致甲状腺不良反应的研究进展  

A Review of Thyroid Adverse Events Produced by PD-1/PD-L1 Inhibitors

作　　者：万宝玉 邓鹏裔 王朋[1] 田金玲[1] 胡涛[1] 严凯[1] 代文莉[1] Wan Baoyu;Deng Pengyi;Wang Peng(Key Laboratory of Yichang Nuclear Medical Molecular Imaging,Nuclear Medicine Department of theFirst College of Clinical Medical Science,China Three Gorges University,Yichang CentralPeople’s Hospital,Yichang 443003,China)

机构地区：[1]三峡大学第一临床医学院,宜昌市中心人民医院核医学科,宜昌市核医学分子影像重点实验室,宜昌443003

出　　处：《华中科技大学学报（医学版）》2021年第2期256-260,共5页Acta Medicinae Universitatis Scientiae et Technologiae Huazhong

基　　金：湖北省自然科学基金资助项目(No.2018CFB147);宜昌市医疗卫生科研项目(No.A18-301-14,No.A19-301-08)。

摘　　要：程序性细胞死亡受体1(programmed cell death-1,PD-1)和程序性细胞死亡受体配体1(programmed cell death ligand-1,PD-L1)在肿瘤分期、复发、转移、浸润及预后中发挥着重要的作用,抗PD-1/PD-L1单抗药物在多种肿瘤的治疗中取得了令人鼓舞的进展,但是在治疗的同时也会带来许多不良反应,即免疫相关不良事件(immune-related adverse events,irAEs),其中甲状腺不良反应的发生率可高达10%,严重的甲状腺不良反应可导致死亡,因此抗PD-1/PD-L1单抗药物的安全性还有待进一步研究,该文主要就抗PD-1/PD-L1单抗药物治疗后甲状腺不良反应的发生机制、临床表现、处理措施、预后等方面进行综述。Programmed cell death-1(PD-1)and its ligand(PD-L1)play an important role in tumor stage recurrence,metastasis,infiltration and prognosis,and their inhibitors have made encouraging progress in the treatment of many tumors.However,PD-1/PD-L1 inhibitors have brought a lot of immune-related adverse events(irAEs).the incidence of thyroid adverse events can be as high as 10%,severe irAEs of thyroid can lead to death,so the safety of PD-1/PD-L1 inhibitors remains to be further researched.In this review,we will mainly introduce the mechanism,clinical manifestation,treatment and prognosis of thyroid adverse events produced by PD-1/PD-L1 inhibitors.

关 键 词：抗PD-1/PD-L1单抗 甲状腺 免疫相关不良反应 

分 类 号：R581[医药卫生—内分泌]